1. Home
  2. SPRY vs SII Comparison

SPRY vs SII Comparison

Compare SPRY & SII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRY
  • SII
  • Stock Information
  • Founded
  • SPRY 2015
  • SII 2008
  • Country
  • SPRY United States
  • SII Canada
  • Employees
  • SPRY N/A
  • SII N/A
  • Industry
  • SPRY Biotechnology: Pharmaceutical Preparations
  • SII Finance: Consumer Services
  • Sector
  • SPRY Health Care
  • SII Finance
  • Exchange
  • SPRY Nasdaq
  • SII Nasdaq
  • Market Cap
  • SPRY 1.2B
  • SII 1.1B
  • IPO Year
  • SPRY N/A
  • SII N/A
  • Fundamental
  • Price
  • SPRY $12.60
  • SII $44.73
  • Analyst Decision
  • SPRY Strong Buy
  • SII
  • Analyst Count
  • SPRY 4
  • SII 0
  • Target Price
  • SPRY $28.75
  • SII N/A
  • AVG Volume (30 Days)
  • SPRY 2.0M
  • SII 148.2K
  • Earning Date
  • SPRY 03-20-2025
  • SII 05-07-2025
  • Dividend Yield
  • SPRY N/A
  • SII 2.71%
  • EPS Growth
  • SPRY N/A
  • SII 19.38
  • EPS
  • SPRY 0.08
  • SII 1.91
  • Revenue
  • SPRY $89,149,000.00
  • SII $178,655,000.00
  • Revenue This Year
  • SPRY $41.49
  • SII N/A
  • Revenue Next Year
  • SPRY $80.23
  • SII $8.66
  • P/E Ratio
  • SPRY $156.13
  • SII $22.84
  • Revenue Growth
  • SPRY 297063.34
  • SII 18.03
  • 52 Week Low
  • SPRY $7.55
  • SII $36.76
  • 52 Week High
  • SPRY $18.51
  • SII $48.00
  • Technical
  • Relative Strength Index (RSI)
  • SPRY 53.51
  • SII 63.01
  • Support Level
  • SPRY $12.08
  • SII $44.23
  • Resistance Level
  • SPRY $13.22
  • SII $45.66
  • Average True Range (ATR)
  • SPRY 0.91
  • SII 1.07
  • MACD
  • SPRY 0.12
  • SII 0.25
  • Stochastic Oscillator
  • SPRY 41.07
  • SII 99.28

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

Share on Social Networks: